Board of Directors

Ines Holzbaur, Ph.D, AmorChem Venture Fund

Inès is a co-founder and managing partner of AmorChem, an early-stage life sciences investment fund. It has played a key role in creating its investment model and developing its operations. She is involved in several investments and transactions with major pharmaceutical companies, including Hoffmann, La Roche and Vertex. She also served as Chair of the Board of NuChem Sciences until its management buyout. She is very active in the life sciences ecosystem and sits on several boards and committees, including the CIHR, the Quebec Biotechnology Innovation Centre and the Nanomedicine Innovation Network. Inès holds a PhD in Chemistry from the University of Cambridge and certifications in leadership and private equity governance.

Tomio Kikuya, Senju Pharmaceutical Co., Ltd.

M. Tomio Kikuya is Director, New Business Creation and Development of Senju Pharmaceutical Co. Ltd. He joined Senju in 1992 and worked in different positions in Licensing, International Business, Los Angeles Office, Amsterdam Office, Business Development, and Corporate Planning before taking on his current role.

Garth Cumberlidge, PhD, SemaThera Inc.

Garth is the President & Chief Executive Officer of SemaThera. Additionally, he is chairman of the Board of Directors of Eyevensys, a French biotechnology company developing novel non-viral gene therapy platform for visionthreatening ocular diseases. He is the former President and Chief Executive Officer of Mimetogen Pharmaceuticals Inc., a biotechnology company developing novel neuroprotective and neurostimulatory compounds for the treatment of ocular diseases. Prior to Mimetogen, Dr. Cumberlidge served as President & CEO of Qbiogene Inc., a company providing life sciences research products and custom cGMP manufacturing services to academic, biotechnology and pharmaceutical researchers worldwide. Dr. Cumberlidge holds degrees in Biochemistry and Genetics from the University of London (U.K.) and in Molecular Genetics from the Max-Planck-Institute for Molecular Genetics, Berlin (Germany).

Andreas Stahl, MD, Klinik fuer Augenheilkunde, Universitaetsmedizin, Greifswald.

Prof. Dr. Andreas Stahl began his clinical career at the Freiburg University Eye Clinic. Research residencies in 2004 and 2008 – 2010 at Harvard Medical School, Boston (USA). Since 2014, he has headed the Department of Outpatient Retinal Surgery in Freiburg. His medical focus lies in the entire spectrum of conservative and operative retinology. Prof. Stahl is the author of numerous specialist publications and clinical therapy studies as well as a member of the Executive Board of the German Retinological Society. He is also a guideline officer for the screening and treatment of retinopathy of prematurity.

630 Bld Rene-Levesque W, 20th Floor
Montreal, Quebec H3B 1S6
Canada

General Inquiries: info@semathera.com